Literature DB >> 6932919

Clonogenic cell survival curves for human melanoma xenografts using agar diffusion chamber and lung colony assays.

P J Selby, J M Thomas.   

Abstract

Studies using 2 different cloning assays to grow colonies and measure cell survival after treatment of human melanoma xenografts are reported and reviewed. Clonogenic cell survival curves were constructed for 5 melanoma xenografts with a clinically relevant range of drugs, using a soft agar diffusion chamber assay. Cells in colonies were similar to human melanoma cells in morphology, histochemistry, ultrastructure and antigenicity and xenograft tumours could be grown from the colonies. The survival curves were compatible with the known clinical patterns of response of malignant melanoma. The sensitivities of the xenografts correlated with the response of the same tumour in the patient when assessable. In 2 xenograft lines, it proved possible to grow colonies in the lungs of immune deprived mice. Studies of drug sensitivity using this lung colony assay agreed closely with the soft agar assay. It is concluded that the measurement of clonogenic cell survival can be a valuable endpoint in the assessment of the response of some xenograft tumours to therapy. The agreement between the 2 assays in which colonies were grown under widely different conditions decreases the likelihood that cells cloned represent an atypical subpopulation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6932919      PMCID: PMC2149189     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  8 in total

1.  Proceedings: An "in vitro" colony assay for human humours: radiation survival in a pancreatic tumour xenograft.

Authors:  V D Courtenay; J Mills
Journal:  Br J Radiol       Date:  1976-06       Impact factor: 3.039

2.  In vitro radiation response of cells from four human tumors propagated in immune-suppressed mice.

Authors:  I E Smith; V D Courtenay; J Mills; M J Peckham
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

3.  Survival curve of a human melanoma in nude mice.

Authors:  M Guichard; C Gosse; E P Malaise
Journal:  J Natl Cancer Inst       Date:  1977-06       Impact factor: 13.506

4.  A comparison of the chemosensitivity of a primary tumour and its metastases using a human tumour xenograft.

Authors:  P J Selby; J M Thomas; M J Peckham
Journal:  Eur J Cancer       Date:  1979-12       Impact factor: 9.162

5.  A lung colony clonogenic cell assay for human malignant melanoma in immune-suppressed mice and its use to determine chemosensitivity, radiosensitivity and the relationship between tumour size and response to therapy.

Authors:  J M Thomas
Journal:  Br J Surg       Date:  1979-10       Impact factor: 6.939

6.  An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents.

Authors:  V D Courtenay; J Mills
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

7.  Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation.

Authors:  P J Selby; J M Thomas; P Monaghan; J Sloane; M J Peckham
Journal:  Br J Cancer       Date:  1980-01       Impact factor: 7.640

8.  A colony-forming assay for human tumour xenografts using agar in diffusion chambers.

Authors:  I E Smith; V D Courtenay; M Y Gordon
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

  8 in total
  3 in total

Review 1.  Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients.

Authors:  P J Selby; D Raghavan
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

2.  Clonogenic cell survival in cryopreserved human tumour cells.

Authors:  P J Selby; G G Steel
Journal:  Br J Cancer       Date:  1981-02       Impact factor: 7.640

Review 3.  Human tumour xenografts: a critical appraisal.

Authors:  G G Steel; M J Peckham
Journal:  Br J Cancer Suppl       Date:  1980-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.